Dual Targeting of Pim and PI3 Kinases in Mature T‐Cell Lymphoma
Authors:
Open Access
- 31 March 2025
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 115 (1) , 82-95
Abstract
Provirus Integration site for Moloney leukemia virus (Pim) family members are well‐known oncogenes, with an expression that is restricted to few cell types including hematopoietic cells in adult organisms, making it a promising target for lymphoma treatment. Indeed, previous studies in mature T‐cell lymphoma (mTCL) cells revealed frequent upregulation of Pim expression. Nevertheless, inhibition of Pim kinases showed only minor effects on the viability of mTCL cells so far. Thus, we here addressed cellular responses to therapeutic inhibition of Pim kinases and identified a PI3K/Akt‐driven activation of mTOR as a significant escape mechanism mitigating the anti‐lymphoma effects of Pim inhibition. Indeed, dual inhibition of Pim and PI3 kinases showed synergistic anti‐lymphoma effects in vitro through downregulation of mTOR‐induced protein translation and mitigation of BCL‐xL‐mediated anti‐apoptotic mechanisms. Based on this finding, we next explored the therapeutic potential of the dual Pim/PI3K inhibitor IBL‐202 in mTCL cell lines. Strikingly, IBL‐202 strongly induced cell‐cycle‐dependent cell death in cell lines of different mTCL subtypes. Together, our study provides mechanistic evidence supporting a therapeutic strategy of dual Pim‐ and PI3‐kinase inhibition in mature T‐cell lymphoma.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (DFG 442249343)
- Deutsche Krebshilfe (70113602)
This publication has 37 references indexed in Scilit:
- The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myelomaLeukemia, 2019
- Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitorsEuropean Journal of Medicinal Chemistry, 2019
- Molecular basis underlying resistance to Mps1/TTK inhibitorsOncogene, 2015
- Targeting the Pim kinases in multiple myelomaBlood Cancer Journal, 2015
- PIM kinase (and Akt) biology and signaling in tumorsPharmacology & Therapeutics, 2015
- BH3 profiling in whole cells by fluorimeter or FACSMethods, 2013
- Fiji: an open-source platform for biological-image analysisNature Methods, 2012
- The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates the G2/M specific phosphatase Cdc25CThe International Journal of Biochemistry & Cell Biology, 2006
- A small molecule–kinase interaction map for clinical kinase inhibitorsNature Biotechnology, 2005
- Pim‐1 kinase promotes inactivation of the pro‐apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper siteFEBS Letters, 2004